WallStreetZenWallStreetZen

NASDAQ: HALO
Halozyme Therapeutics Inc Stock

$44.71-0.68 (-1.5%)
Updated May 17, 2024
HALO Price
$44.71
Fair Value Price
$16.98
Market Cap
$5.69B
52 Week Low
$31.86
52 Week High
$46.16
P/E
18.25x
P/B
32x
P/S
5.98x
PEG
0.44x
Dividend Yield
N/A
Revenue
$862.99M
Earnings
$318.80M
Gross Margin
78.5%
Operating Margin
47.61%
Profit Margin
36.9%
Debt to Equity
9.36
Operating Cash Flow
$431M
Beta
0.82
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

HALO Overview

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HALO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HALO ($44.71) is overvalued by 163.23% relative to our estimate of its Fair Value price of $16.98 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
HALO ($44.71) is not significantly undervalued (163.23%) relative to our estimate of its Fair Value price of $16.98 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
HALO ($44.71) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HALO due diligence checks available for Premium users.

Be the first to know about important HALO news, forecast changes, insider trades & much more!

HALO News

Valuation

HALO fair value

Fair Value of HALO stock based on Discounted Cash Flow (DCF)
Price
$44.71
Fair Value
$16.98
Overvalued by
163.23%
HALO ($44.71) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HALO ($44.71) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HALO ($44.71) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

HALO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
18.25x
Industry
8.47x
Market
30.97x
HALO is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
HALO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

HALO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
32x
Industry
6.01x
HALO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HALO price to earnings growth (PEG)

For valuing profitable companies with growth potential
HALO is good value based... subscribe to Premium to read more.
PEG Value Valuation

HALO's financial health

Profit margin

Revenue
$195.9M
Net Income
$76.8M
Profit Margin
39.2%
HALO's Earnings (EBIT) of $410.85M... subscribe to Premium to read more.
Interest Coverage Financials
HALO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.8B
Liabilities
$1.7B
Debt to equity
9.36
HALO's short-term assets ($873.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HALO's long-term liabilities ($1.53B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HALO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HALO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$129.4M
Investing
-$82.7M
Financing
-$489.0k
HALO's operating cash flow ($431.03M)... subscribe to Premium to read more.
Debt Coverage Financials

HALO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
HALO$5.69B-1.50%18.25x32.00x
BBIO$5.63B-3.06%-9.34x-5.37x
IONS$5.45B-0.82%-13.97x18.37x
IBRX$5.29B-1.29%-7.02x-7.65x
EXEL$6.09B-1.51%32.67x2.86x

Halozyme Therapeutics Stock FAQ

What is Halozyme Therapeutics's quote symbol?

(NASDAQ: HALO) Halozyme Therapeutics trades on the NASDAQ under the ticker symbol HALO. Halozyme Therapeutics stock quotes can also be displayed as NASDAQ: HALO.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.

What is the 52 week high and low for Halozyme Therapeutics (NASDAQ: HALO)?

(NASDAQ: HALO) Halozyme Therapeutics's 52-week high was $46.16, and its 52-week low was $31.86. It is currently -3.14% from its 52-week high and 40.33% from its 52-week low.

How much is Halozyme Therapeutics stock worth today?

(NASDAQ: HALO) Halozyme Therapeutics currently has 127,274,000 outstanding shares. With Halozyme Therapeutics stock trading at $44.71 per share, the total value of Halozyme Therapeutics stock (market capitalization) is $5.69B.

Halozyme Therapeutics stock was originally listed at a price of $4.25 in Mar 16, 2004. If you had invested in Halozyme Therapeutics stock at $4.25, your return over the last 20 years would have been 952%, for an annualized return of 12.49% (not including any dividends or dividend reinvestments).

How much is Halozyme Therapeutics's stock price per share?

(NASDAQ: HALO) Halozyme Therapeutics stock price per share is $44.71 today (as of May 17, 2024).

What is Halozyme Therapeutics's Market Cap?

(NASDAQ: HALO) Halozyme Therapeutics's market cap is $5.69B, as of May 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Halozyme Therapeutics's market cap is calculated by multiplying HALO's current stock price of $44.71 by HALO's total outstanding shares of 127,274,000.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.